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Abstract
Introduction: Despite recent and robust economic growth across the Asia-Pacific region, the majority of low- and middle-income
countries in the region remain dependent on some donor support for HIV programmes. We describe the availability of bilateral
and multilateral official development assistance (ODA) for HIV programmes in the region.
Methods: The donor countries considered in this analysis are Australia, Canada, Denmark, France, Germany, Netherlands,
Norway, Sweden, the United Kingdom and the United States. To estimate bilateral and multilateral ODA financing for HIV
programmes in the Asia-Pacific region between 2004 and 2013, we obtained funding data from the Organisation for Economic
Co-operation and Development Creditor Reporting System database. Where possible, we checked these amounts against the
funding data available from government aid agencies. Estimates of multilateral ODA financing for HIV/AIDS were based on the
country allocations announcement by the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) for the period
2014 to 2016.
Results: Countries in the Asia-Pacific region receive the largest share of aid for HIV from the Global Fund. Bilateral funding for
HIV in the region has been relatively stable over the last decade and is projected to remain below 10% of the worldwide
response to the epidemic. Bilateral donors continue to prioritize ODA for HIV to other regions, particularly sub-Saharan Africa;
Australia is an exception in prioritizing the Asia-Pacific region, but the United States is the bilateral donor providing the greatest
amount of assistance in the region. Funding from the Global Fund has increased consistently since 2005, reaching a total of
US$1.2 billion for the Asia-Pacific region from 2014 to 2016.
Conclusions: Even with Global Fund allocations, countries in the Asia-Pacific region will not have enough resources to meet their
epidemiological targets. Prevention funding is particularly vulnerable and requires greater domestic leadership and coordination.
Bilateral donors are still crucially important in the response to HIV throughout the Asia-Pacific region.
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Introduction
All low-income and most lower-middle-income countries in
the Asia-Pacific region are heavily reliant on international
funding for HIV programmes (Figure 1). This dependence has
persisted despite robust economic growth across Asia and the
Pacific over the past decade. However, there are likely to be
significant cuts to international funding for HIV programmes in
the region following the adoption of a new funding model by
the region’s largest donor, the Global Fund to Fight AIDS,
Tuberculosis and Malaria (the Global Fund). The new model
uses epidemiological and economic criteria to determine
funding eligibility. A number of countries in Asia and the
Pacific are above or will soon rise above the Global Fund’s
threshold of $2000 gross national income per capita; they will
therefore receive less funding from the Global Fund in the
future. This new funding model reflects an expectation on
governments in the Asia-Pacific region to be less reliant on
external aid and invest more of their own resources in the
health and wellbeing of their populations [1].
It is important to estimate not only how much official
development assistance (ODA) for HIV will be available for
countries in the Asia-Pacific region but also the likely sources
of this funding. This study assesses the outlook for external
assistance for HIV in the Asia-Pacific region.
Methods
We sought to describe the availability of bilateral and
multilateral (Global Fund) ODA for HIV programmes in the
Asia-Pacific region. The recipient countries considered in
this analysis are Afghanistan, Bangladesh, Bhutan, Cambodia,
China, Fiji, India, Indonesia, Kiribati, Korea, Laos, Malaysia,
Maldives, Marshall Islands, Micronesia, Mongolia, Myanmar,
Nepal, Pakistan, Palau, Papua New Guinea, Philippines, Samoa,
Sri Lanka, Solomon Islands, Thailand, Timor-Leste, Tonga, Tuvalu,
Vanuatu and Vietnam. These 31 countries together make up
the World Bank’s definition of the low- and middle-income
countries in the East Asia, Pacific and South Asia regions, which
we refer to as the Asia-Pacific region.
To estimate multilateral and bilateral ODA financing for
HIV between 2004 and 2013, we searched the Organisation
for Economic Co-operation and Development (OECD) Creditor
Reporting System (CRS) database for funding data in Subsectors
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13040 (STD control including HIV/AIDS) and 16064 (Social
mitigation of HIV/AIDS). Where possible, we checked these
amounts against the funding data available from govern-
ment aid agencies. To estimate multilateral ODA financing
for HIV/AIDS for 2014 to 2016, we used the country alloca-
tions announced by the Global Fund for this period, with
health-system-strengthening funding excluded. Given that the
Global Fund has provided a significant share of multilateral
HIV financing in the Asia-Pacific region, we take its funding
allocations as a proxy for the total amount of multilateral
funding that will be available. For comparative purposes,
and to understand whether HIV still represents an ODA prior-
ity for donor countries, we also estimated country donor
contributions to the Global Fund that are HIV-attributable.
We obtained estimates of donor contributions between 2005
and 2013 and pledges for 2014 to 2016 from the Global Fund’s
website [2].
Results
International aid for HIV in the Asia-Pacific region,
2004 to 2013
Major sources of international aid for HIV
The largest international contributors to HIV programmes
in the Asia-Pacific region between 2004 and 2013 were
the Global Fund and the US government, which together
provided over 60% of all international funding to the region
(Figure 2a, final bar). The remaining 40% of international
aid for HIV in the region came from the UK government, the
Australian government, development banks, European and
other OECD Development Assistance Committee govern-
ments and other multilateral agencies. The primary sources
of funding differ by subregion, with the Pacific receiving 80%
of its funding from the Australian government, while South and
East Asia each receive 80% from the Global Fund and the US
and UK governments (Figure 2a, first three bars). Globally, the
share of aid for HIV provided bilaterally is around three-quarters
($6.4 billion annually) [3]; between 2004 and 2013, the bilateral
share of aid to South and East Asia was lower than the global
average (36 and 53%, respectively), but much higher than the
global average in the Pacific.
The total share of funding provided by the US government
and the Global Fund remained relatively stable over the
decade, but the share provided bilaterally by the US govern-
ment decreased from 42% in 2004 to 17% in 2013, with this
decline offset by increases in the Global Fund share (from23 to
55%). The relative importance of the US government as a
donor is reinforced by the fact that they were responsible for
between 30 and 45% of the annual total pledges to the Global
Figure 1. International versus domestic funding for HIV/AIDS programmes in Asia-Pacific, 2012. (Source: UNAIDS AIDS DataHub [www.
aidsdatahub.org].)
Stuart RM et al. Journal of the International AIDS Society 2015, 18:20004
http://www.jiasociety.org/index.php/jias/article/view/20004 | http://dx.doi.org/10.7448/IAS.18.1.20004
2
Fund between 2001 and 2016; adjusting for this, we estimate
that around one-third of HIV funding to the region was
contributed by theUS government, either indirectly or directly.
Growth in international aid for HIV
Annual international funding for HIV in the Asia-Pacific
region increased by an average of 10% per annum bet-
ween 2004 and 2013, with almost all of this annual average
increase (nine percentage points) attributable to the growth
in Global Fund allocations (Figure 2b). Allocations from other
development banks andmultilateral agencies remained essen-
tially flat over this period. Increases in bilateral ODA from
Australia contributed two percentage points to the total
growth in international funding over the decade to 2013,
while decreases from the UK government subtracted one
percentage point.
Figure 2. Trends and growth in international aid for HIV in the Asia-Pacific region. (a) The major sources of international aid for HIV
in the Asia-Pacific region, 2004 to 2013. (Source: OECD-CRS database.) (b) Growth in international aid for HIV in the Asia-Pacific region,
2004 to 2013. (Source: OECD-CRS database.)
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Bilateral donors’ preferences and patterns
Between 2004 and 2013, 99% of bilateral funds for HIV
disbursed in the Asia-Pacific region and recorded in the CRS
database originated from 10 donor countries: the United
States, the United Kingdom, Australia, Germany, Sweden,
Norway, Canada, the Netherlands, France and Japan. In 2013,
these 10 countries allocated US$238 million to the Asia-
Pacific region. In the same year, these 10 countries pledged
US$3060 million to the Global Fund, of which an estimated
9%, or US$280 million, was allocated to HIV programmes in
the Asia-Pacific region. All countries except Australia com-
mitted more to HIV programmes in the region via their Global
Fund contributions than they did bilaterally.
Of the 10most significant bilateral donors in the Asia-Pacific
region, all except Australia contribute far more to countries
in other regions than they do to countries in the Asia-Pacific.
Just under 85% of all bilateral ODA for HIV from these
10 countries was allocated to sub-Saharan Africa, compared to
10% allocated to the Asia-Pacific region (Figure 3a). The
proportion of all bilateral funding allocated to the Asia-Pacific
region has been steadily decreasing between 2004 and 2013,
from 17% in 2004 to 6% in 2013, mostly driven by declines in
the share allocated to the region by the regions’ two largest
bilateral donors, the United States and the United Kingdom.
However, several countries, including Australia, Germany,
Japan and the Netherlands, increased the proportion of their
total HIV aid budgets allocated to the region over this period
(Figure 3b).
International aid for HIV per person infected
In order to estimate whether the distribution of ODA for HIV
is roughly in line with the distribution of the epidemic, we
calculate the amount of ODA for HIV per person infected for
each region (Figure 4). While the number of PLHIV is only a
very rough indicator of the epidemic burden, we can never-
theless observe that the distribution of total ODA is more even
once the scale of the epidemic has been taken into account.
The Asia-Pacific region received approximately US$150 per
PLHIV in 2013, compared to a global average of US$190.
How international aid for HIV is spent
We used the UN’s Global AIDS Response Progress Reporting
database to investigate how funds allocated for HIV were
spent over the period from 2005 to 2012 (Figure 5). Interna-
tional aid is particularly important for funding prevention
programmes, with around 60% of prevention funding attribu-
table to international donors. Other areas that are heavily
dependent on international aid include programme manage-
ment and administration strengthening (60% international)
and incentives for human resources (65% international).
The region as a whole is relatively self-sufficient when it comes
to funding treatment programmes, with 80% of treatment
funded domestically.
Aid for HIV and total health aid
The results of a 2008WHO investigation into the CRS database
found that funding for HIV/AIDS accounted for almost one-
third (32%) of total health ODA for the period 2002 to 2006.
We found that this proportion has not decreased significantly
since then, with funding for HIV/AIDS accounting for 30% of
total health ODA between 2007 and 2013.
Aid for HIV in the Asia-Pacific region in 2014 and beyond
Global Fund allocations for HIV
HIV-attributable donor pledges to the Global Fund reached
US$12 billion in the fourth allocation (2014 to 2016) round,
representing a 30% increase over the previous round. All donor
countries have increased their contributions to the Global
Fund since 2005, with most of the increases attributable to
previous commitments and current pledges by the United
States. Global Fund allocations for HIV have increased across
all world regions, including a fourfold increase in funding from
the Global Fund for HIV programmes in the Asia-Pacific region
since 2005.
The Global Fund has currently allocated 16% of total
funding excluding existing health-system-strengthening funds
to the Asia-Pacific region. This represents a total of US$1.2
billion over the three-year allocation period, 2014 to 2016,
with all low- and middle-income countries in Asia remaining
on the Global Fund’s eligibility list in the fourth replenish-
ment round. Countries in sub-Saharan Africa receive the vast
majority (69%) of Global Fund allocations.
Bilateral allocations for HIV
We previously identified 10 bilateral donors that contributed
99% of funds for HIV over the past decade. We examined
the national budgets of nine of these 10 countries (budgets
for Germany and Japan were not available at the time of
data collection) and estimate that a total of US$204 million in
ODA for HIV was budgeted the Asia-Pacific region in 2014,
more than half of which is attributable to the United States.
These nine governments pledged over six times this amount
(US$1.3 billion) to the Global Fund.
Beyond 2014, some of the larger contributors of HIV funding
to the Asia-Pacific region have already or are expected to de-
crease their ODA budgets. While Australia’s assistance has
increased in recent years, Australia’s overall fiscal policy and
strategic foreign policy directionmean that international assis-
tance for HIV will likely stagnate or decrease over the next
several years [4]. The United States and Netherlands are
also expected to reduce their ODA budgets for HIV through
to 2016.
Discussion
Across the Asia-Pacific region, governments will require
continued ODA for HIV to respond to their national HIV epi-
demics and achieve epidemiological targets [5,6]. There is
already a large resource gap between current HIV funding and
the level required in order to bring about targeted reductions
in HIV-related incidence and mortality in Asia [6,7]. Trends in
ODA for HIV suggest that this gap is likely to widen.
While bilateral funding for HIVat a global level has increased
in previous years, donors continue to concentrate ODA for HIV
to countries in sub-Saharan Africa. Pledges to the Global Fund
and continued bilateral ODA for HIV in sub-Saharan Africa
suggest that HIV still represents a funding priority for donors.
However, bilateral ODA for HIV in the Asia-Pacific region has
remained close to constant over the decade to 2013 and
is a relatively low priority among most bilateral donors.
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Bilateral donors are already decreasing funding for HIV pro-
grammes in middle-income countries across the Asia-Pacific
region for future years due to governments’ intentions to
refocus HIV funding and fiscal austeritymeasures following the
global financial crisis [5]. While most donors have displayed a
continued preference for providing HIV assistance bilaterally,
most countries in the Asia-Pacific region can continue to expect
to receive the majority of external assistance for HIV multi-
laterally. The 2014 OECD Development Assistance Committee
survey on donors’ forward-spending plans indicated that
overall (HIV- and non-HIV-related) programmed aid to low-
income countries in Africa and elsewhere will decline. The
survey also suggests a continued donor focus in the medium
term on middle-income countries, including some projected
increases in programmable aid for middle-income countries
across the Asia-Pacific region. However, much of these in-
creases are likely to take the form of soft loans and are unlikely
to be HIV-specific [8].
Figure 3. Bilateral donors’ preferences and patterns. (a) Bilateral funding for HIV by global region, 2004 to 2013. (Source: OECD-CRS
database.) (b) The share of bilateral funding for HIV allocated to the Asia-Pacific region, 2004 to 2013. (Source: OECD-CRS database.)
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TheGlobal Fund’smodel of allocating funding toHIVaccording
to epidemiological and economic criteria means that all low-
and middle-income countries in the region currently remain
eligible for HIV funding. A number of countries in the Asia-
Pacific region  including the three largest, China, Pakistan and
Indonesia  are presently among the Fund’s designated ‘‘highest
impact’’ subset, for which Global Fund investments are believed
to have the highest impact on outcomes [9]. Yet there is con-
siderable uncertainty about whether countries will remain
eligible for Global Fund resources past 2016 as their economic
growth continues.
While there is currently no consensus on what constitutes a
reasonable domestic contribution to HIV responses [10,11],
governments of recipient countries are now expected by the
international community to transition towards self-sufficiency in
financing their HIV programmes to align with economic growth
across the region [5]. There have already been significant steps
in this direction within the Asia-Pacific region: between 2004
and 2013, the number of people in the region accessing anti-
retroviral therapy increased from 70,000 to 1,250,000, and an
estimated 80% of these treatment costs were funded from
domestic sources. However, despite high-level political commit-
ment to funding HIV responses [5], most national governments
across the Asia-Pacific region have expressed uncertainty on
the question of where to find additional funding for HIV within
their domestic budgets. HIV prevention programmes for key
affected populations, which up until now have been primarily
funded by donors, are particularly at risk [12].
An important concern for providers of international aid
is the extent to which international aid to governmental
Figure 4. International aid for HIV per PLHIV, 2013. (Sources: OECD CRS database; UNAIDS.)
Figure 5. Allocation of funding among HIV programs in the Asia-Pacific region, 20052012. (Source: Global AIDS Response Progress
Reporting database)
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sectors might crowd out the government and private sectors
in some countries as the government reallocates their
funds to other priority areas. This concept of aid displace-
ment (or fungibility) implies that donor funds intended for
health are effectively used to fund other things. The average
fungibility of aid for HIV has not been well established, with
various publications reporting conflicting messages [13,14].
Competing domestic budgetary priorities across the health
sector and political agendas mean that domestic resources will
not automatically replace declining ODA [6,15]. This issue is an
open question into which further research would be very
welcome.
Although national governments should continue to make
progress towards achieving domestic ownership of their
HIV responses [16], it is clear that the transition to domestic
funding will require a phased approach [5], including provi-
sions that respond to countries’ existing politics and policies
that affect governments’ abilities to bridge financial gaps.
Consideration of the policy environment in recipient countries
has not tended to be greatly influential in donor aid allocation
decisions [1719]. However, policies and laws against the
often marginalized members of key affected populations at
higher risk of HIV infection must be addressed to facilitate
effective prevention programmes [20]. This action is especially
important because these critical programmes are the most
vulnerable to being dismantled as they are currently mainly
funded from international sources. Although it does not explic-
itly consider the political environment of recipient countries, the
Global Fund’s use of qualitative criteria to adjust aid allocation
decisions within its new funding model, including past pro-
gramme performance, risk and absorptive capacity [21], are
positive steps in this direction. However, the Global Fund’s
emphasis on funding to achieve the greatest programme impact
[22] means that there is still likely room for improvement in
balancing considerations of efficiency and equity [23].
The experience of low national HIV prevalence and re-
cent economic growth among countries in the Asia-Pacific
region does not preclude their continued need for donor
assistance, at least in the short term. Until the principle of
health for all [24] can be fully realized on the political and
budgetary agendas of governments across the Asia-Pacific
region, countries will need donors’ continued fiscal support
for HIV. In addition to the total amount of aid available for
HIV, the mode of aid disbursement has important implica-
tions for aid effectiveness [25,26]. The increased use of soft
loans in the future may mean middle-income Asian and
Pacific countries may expect more ODA funding in general
in the future [8]. However, the impact of this on HIV financing
is uncertain. Despite some weaknesses [27,28], the shift
towards multilateral disbursement of ODA for HIV may
help to overcome some of the challenges in achieving aid
harmonization [29,30] that can result from having multiple
sources of bilateral aid [31]. This has become a pertinent
issue in Asia as the number of bilateral donors has prolif-
erated over the last decade [32]. Potential advantages of
multilateral disbursement of ODA include increased harmo-
nization of aid flows and enhanced collective action for HIV
in the region [33,34].
The current study reviewed trends in bilateral and multi-
lateral aid for HIV in the Asia-Pacific region. However, it is
important to note that this analysis did not include all relevant
multilateral and bilateral donors in the Asia-Pacific region.
In particular, data for China were not available at the time of
data collection. The statistics on international HIV-specific
assistance reported by the OECD CRS do not include all forms
of international assistance. In addition, the CRS data may
not include certain funding streams provided by donors, such
as HIV components of mixed grants to non-governmental
organizations.
Conclusions
Countries in Asia-Pacific are increasingly taking leadership
for the care and treatment of their populations of people
living with HIV, as evidenced by increased coverage of anti-
retroviral therapy and increased proportional funding con-
tributions from domestic sources. However, most countries
in the region are heavily reliant on international sources,
particularly the Global Fund and PEPFAR (complemented
by bilateral sources), for their HIV prevention programmes.
Specifically, prevention programmes for people most at risk
of acquiring HIV are almost entirely funded from interna-
tional sources. Domestically funded prevention programmes
are all too often non-targeted or targeted at general lower
risk populations [15]. With all of the accumulated knowl-
edge and evidence, and especially considering the future
financing landscape, domestically funded HIV programmes
need to deliver effective prevention strategies that focus on
key populations and are designed to respond to local con-
ditions and epidemiology. Developing and implementing these
prevention programmes demands strong domestic leadership
and may ultimately lead to better coordination of the HIV re-
sponse in the longer term. However, in the medium term, the
Global Fund and bilateral donors will remain crucially important
to the HIV response in the Asia-Pacific region.
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